30 Sept 2026, 13:04
Securities Administration—
ACWACTINOGEN MEDICAL LIMITED
Announcement history available from 1 August 2025
Fromto
23 Sept 2026, 12:35
Securities Administration—
23 Sept 2026, 12:35
Securities Administration—
23 Sept 2026, 12:34
Securities AdministrationMS
23 Sept 2026, 08:47
Company UpdateMS
16 Sept 2026, 12:43
Securities Administration—
15 Sept 2026, 14:34
Securities Administration—
11 Sept 2026, 15:54
Securities Administration—
9 Sept 2026, 12:54
Director Interests—
9 Sept 2026, 12:40
Securities Administration—
9 Sept 2026, 10:11
Presentations—
8 Sept 2026, 14:52
Securities Administration—
7 Sept 2026, 16:39
Securities Administration—
4 Sept 2026, 15:55
ASX QueryMS
3 Sept 2026, 15:04
Securities Administration—
1 Sept 2026, 10:14
Securities Administration—
1 Sept 2026, 10:12
Company UpdateMS
28 Aug 2026, 15:58
Securities Administration—
28 Aug 2026, 14:46
Director Interests—
28 Aug 2026, 14:43
Director Interests—
28 Aug 2026, 14:36
Securities Administration—
27 Aug 2026, 16:42
Company Administration—
27 Aug 2026, 16:41
Company Administration—
27 Aug 2026, 16:27
Financial ResultsMS
27 Aug 2026, 16:26
Financial ResultsMS
20 Aug 2026, 14:46
Director Interests—
20 Aug 2026, 14:40
Securities Administration—
17 Aug 2026, 14:26
Director Interests—
17 Aug 2026, 14:14
Securities Administration—
12 Aug 2026, 09:14
Presentations—
10 Aug 2026, 16:38
Company Administration—
10 Aug 2026, 11:33
Securities Administration—
10 Aug 2026, 09:12
Securities Administration—
6 Aug 2026, 08:27
Presentations—
5 Aug 2026, 12:43
Securities Administration—
5 Aug 2026, 12:08
Presentations—
30 July 2026, 10:03
Quarterly ReportsMS
28 July 2026, 15:19
Securities Administration—
21 July 2026, 13:41
Securities Administration—
20 July 2026, 09:33
Company UpdateMS
13 July 2026, 17:24
Other—
13 July 2026, 08:32
Company Update—
8 July 2026, 08:40
Presentations—
25 June 2026, 14:11
Substantial Holders—
24 June 2026, 13:48
Director Interests—
24 June 2026, 13:45
Securities Administration—
23 June 2026, 10:39
Meetings & Governance—
18 June 2026, 15:02
Securities Administration—
18 June 2026, 08:57
Company UpdateMS
1 June 2026, 08:52
Company Update—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 30 Sept 2026, 13:04 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 23 Sept 2026, 12:35 | Options underwriting cleansing notice | Securities Administration | — | 06018 | |
| 23 Sept 2026, 12:35 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 23 Sept 2026, 12:34 | Underwriting of unlisted options completed | Securities Administration | MS | 06009 | |
| 23 Sept 2026, 08:47 | ACW Alzheimers pivotal trial completes last patient visit | Company Update | MS | 11001 | |
| 16 Sept 2026, 12:43 | Notification of cessation of securities - ACW | Securities Administration | — | 06027 | |
| 15 Sept 2026, 14:34 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 11 Sept 2026, 15:54 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 9 Sept 2026, 12:54 | Appendix 3Y-Dr Geoffrey Brooke | Director Interests | — | 02009 | |
| 9 Sept 2026, 12:40 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 9 Sept 2026, 10:11 | ACW CMO international Xanamem presentation | Presentations | — | 03026 | |
| 8 Sept 2026, 14:52 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 7 Sept 2026, 16:39 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 4 Sept 2026, 15:55 | Response to ASX Price Query | ASX Query | MS | 17003 | |
| 3 Sept 2026, 15:04 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 1 Sept 2026, 10:14 | Proposed issue of securities - ACW | Securities Administration | — | 06013 | |
| 1 Sept 2026, 10:12 | ACW unlisted options fully underwritten | Company Update | MS | 06009, 11001 | |
| 28 Aug 2026, 15:58 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 28 Aug 2026, 14:46 | Appendix 3Y-Dr George Morstyn | Director Interests | — | 02009 | |
| 28 Aug 2026, 14:43 | Appendix 3Y-Dr Geoffrey Brooke | Director Interests | — | 02009 | |
| 28 Aug 2026, 14:36 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 27 Aug 2026, 16:42 | Appendix 4G | Company Administration | — | 03025 | |
| 27 Aug 2026, 16:41 | Corporate Governance Statement | Company Administration | — | 03024 | |
| 27 Aug 2026, 16:27 | ACW FY2026 results and outlook | Financial Results | MS | 03003 | |
| 27 Aug 2026, 16:26 | ACW Appendix 4E and 2026 annual report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 20 Aug 2026, 14:46 | Appendix 3Y - Dr George Morstyn | Director Interests | — | 02009 | |
| 20 Aug 2026, 14:40 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 17 Aug 2026, 14:26 | Appendix 3Y-Malcolm McComas | Director Interests | — | 02009 | |
| 17 Aug 2026, 14:14 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 12 Aug 2026, 09:14 | ACW webinar today, The future of Alzheimers treatment | Presentations | — | 03026, 14014 | |
| 10 Aug 2026, 16:38 | Updated Securities Trading Policy | Company Administration | — | 14013 | |
| 10 Aug 2026, 11:33 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 10 Aug 2026, 09:12 | Notification of cessation of securities - ACW | Securities Administration | — | 06027 | |
| 6 Aug 2026, 08:27 | ACW Bioshares presentation, strong cortisol rationale | Presentations | — | 03026 | |
| 5 Aug 2026, 12:43 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 5 Aug 2026, 12:08 | ACW webinar on the future of Alzheimers treatment | Presentations | — | 14014 | |
| 30 July 2026, 10:03 | June 2026 Quarterly activity report & Appendix 4C | Quarterly Reports | MS | 19004, 19009 | |
| 28 July 2026, 15:19 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 21 July 2026, 13:41 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 20 July 2026, 09:33 | Xanamem depression trial published in British J Psychiatry | Company Update | MS | 11001, 12008 | |
| 13 July 2026, 17:24 | Notification of buy-back - ACW | Other | — | 06023 | |
| 13 July 2026, 08:32 | ACW AAIC poster presentation of XanaMIA trial baseline data | Company Update | — | 11001 | |
| 8 July 2026, 08:40 | ACW senior management presentation at AAIC & internationally | Presentations | — | 03026 | |
| 25 June 2026, 14:11 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 24 June 2026, 13:48 | Appendix 3Y x 5 | Director Interests | — | 02009 | |
| 24 June 2026, 13:45 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 23 June 2026, 10:39 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 18 June 2026, 15:02 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 18 June 2026, 08:57 | ACW third positive XanaMIA trial data committee review | Company Update | MS | 11001 | |
| 1 June 2026, 08:52 | ACW presents XanaMIA population and screening data at ADRF | Company Update | — | 11001 |
1–50 of 130
1 / 3